A roundtable discussion - Should vitamin D analogs be the therapy of preference for ESRD patients with secondary hyperparathyroidism?

During the 33rd Annual Meeting of the American society of Nephrology last O ctober in Toronto, Abbott Laboratories arranged an exclusive interview for Dialysis & Transplantation with two of the leading experts in the field of secondary hyperparathyroidism - Eduardo Slatopolsky, MD, FACP, and Kevin J. Martin, MB, BCh, FACP. The interview took place at the Canadian Hockey Hal l of Fame immediately following a presentation by Drs. Slatopolsky and Mart in (as well as by Adrianna Duso, PhD) to a larger audience on "Vitamin D An alogs: Coming of Age in Clinical Nephrology." Dialysis & Transplantation Editorial Advisory Board member Donald J. Sherra rd, MD- himself a renowned expert in secondary hyperparathyroidism - gracio usly agreed to serve as facilitator of this special roundtable discussion, in which the participants discussed how the management of this disease has evolved over the years to a point where vitamin D analogs have become the s tandard of care.